According to the National Comprehensive Cancer Network (NCCN) guidelines version 1.2025, an evaluation for anemia-related symptoms is recommended when hemoglobin (Hb) levels fall to ≤11.0 g/dL or decrease by ≥2 g/dL from baseline during chemotherapy [5]. The gene discussed is GSTM1; the disease is anemia.